Repligen (NASDAQ:RGEN) Rating Increased to Buy at Benchmark

Repligen (NASDAQ:RGEN) was upgraded by analysts at Benchmark from a “hold” rating to a “buy” rating in a research note issued on Tuesday,Benzinga reports. The firm currently has a $185.00 target price on the biotechnology company’s stock. Benchmark’s target price would indicate a potential upside of 30.78% from the stock’s current price.

RGEN has been the topic of several other research reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Wolfe Research initiated coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target for the company. Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Barclays raised their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings lowered Repligen from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average target price of $165.00.

Repligen Stock Down 0.7%

Shares of NASDAQ:RGEN opened at $141.46 on Tuesday. Repligen has a 12 month low of $100.99 and a 12 month high of $175.77. The company’s 50-day moving average price is $124.38 and its two-hundred day moving average price is $134.49. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.98 billion, a P/E ratio of 157.18, a P/E/G ratio of 2.74 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company posted $0.39 EPS. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts forecast that Repligen will post 1.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen in the 3rd quarter valued at approximately $29,000. Bayforest Capital Ltd bought a new position in shares of Repligen in the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC acquired a new position in Repligen during the fourth quarter worth $33,000. Los Angeles Capital Management LLC acquired a new position in Repligen during the fourth quarter worth $36,000. Finally, Farther Finance Advisors LLC increased its holdings in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after buying an additional 128 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.